Health
FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
Source: U.S. Food and Drug Administration (FDA)
Published:
Source summary — U.S. Food and Drug Administration (FDA)
FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds).
This page reports what the publisher stated. MYITEDU has not independently verified these claims.
Read the original article — U.S. Food and Drug Administration (FDA) ↗
Attribution: Source: U.S. Food and Drug Administration (fda.gov)
Share
Instagram does not support sharing links from websites. Download the card, post it from the Instagram app and paste the caption.
Report a correction
Tell us about an error in this item, its translation, date or attribution. Your contact details stay private and are used only to follow up.